Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magnesium + Prochlorperazine for Migraines in the ED
NCT06904287Phase 3Recruiting
- Sponsor
- Wake Forest University Health Sciences
- Start
- Dec 2025
- Primary completion
- Jun 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of magnesium in migraine (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoint: Mean change in pain at 30 minutes. Started Dec 2025; status: recruiting.
02
Drugs
magnesium
03
Conditions
migraine
Beyond the preview
Go deeper on NCT06904287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06904287.